Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Charles Davidson’s Wexford Capital’s Latest Moves

Charles Davidson’s Wexford Capital has fired a return salvo against Lioneye Capital Management, adding 10,000 shares to their holding of Famous Dave’s of America Inc (NASDAQ:DAVE), and retaking the shareholder lead with 710,725 shares. Wexford Capital also reported reducing their stake in RLJ Entertainment Inc (NASDAQ:RLJE), of whom they are also the largest shareholder, by 83,000 shares to 1.47 million.

Charles Davidson - Wexford Capital

We reported a few days ago on that Stephen V. Raneri’s LionEye Capital Management raised its activist position in Famous Dave’s of America Inc (NASDAQ:DAVE) by  48,900 shares to their holding in the restaurant chain. That gave them a total of 702,900 shares, temporarily making them the largest shareholder of Famous Dave’s among institutional investors until being overtaken again just days later by Wexford.

Wexford is a Greenwich, Connecticut-based hedge fund which was founded in 1994 and now operates several fund portfolios with diverse goals; they have been the top shareholder in Famous Dave’s at the end of each of the first three quarters of 2014, and the largest RLJ shareholder since that company’s IPO in October 2012.

Unlike LionEye, Wexford Capital’s position is passive ever since adding Famous Dave’s of America Inc (NASDAQ:DAVE) to their portfolio in early 2014 and becoming their top shareholder. They got in at the perfect time, when Famous Dave’s was in the middle of a steady rise that would reach its peak in early June, having nearly doubled in value since the beginning of the year at that point. Since then, the stock has retreated somewhat, as restaurant traffic remains sluggish across the industry.

Famous Dave’s of America Inc (NASDAQ:DAVE) operates and franchises restaurants in the United States, where it was founded, as well as in Canada and Puerto Rico, where it’s simply known as Famous Dave’s. The first Famous Dave’s (which sadly burned to the ground late last year) opened in Hayward, Wisconsis in 1994, and since then, 49 additional company-owned restaurants, and 139 franchised restaurants have opened.

In their most recent earnings report for the third quarter of 2014, Famous Dave’s of America Inc (NASDAQ:DAVE) reported a decrease in revenue from $39.5 million to $37.7 million. Same-store revenue from company-owned restaurants open at least 24 months also tumbled 5.7% during the quarter. For the first nine months of 2014, revenue fell from $119.7 million during the first nine months of 2013, to $115.3 million, while same-store sales from company-owned restaurants open at least 24 months fell 5.2%, compared to a 0.9% increase during the same period in 2013.

Other major shareholders of Famous Dave’s of America Inc (NASDAQ:DAVE) in addition to the aforementioned Lioneye Capital Management are Brian Jackelow’s SAB Capital Management, with 634,105 shares, and Jim Simons’ Renaissance Technologies, with 333,600 shares.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.